James F. Reddoch is VP at Royalty Pharma plc (RPRX). They have made 12 open-market trades across 1 company since 2021, most recently 2022-09-28.
CIK 0001814872
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 12 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RPRX | 820,800 | $50.0M |
Shares reported on the most recent Form 4, priced at the 2022-09-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RPRX | SELL | 2022-09-28 | 2022-09-30 | $41.23 | $8.2M | +1.9% | +5.0% | -1.9% |
| RPRX | SELL | 2022-06-08 | 2022-06-10 | $41.56 | $4.2M | +2.8% | +7.0% | +7.6% |
| RPRX | SELL | 2022-05-27 | 2022-05-31 | $41.08 | $3.1M | -1.6% | +2.2% | +2.9% |
| RPRX | SELL | 2022-05-19 | 2022-05-23 | $40.44 | $3.0M | +2.5% | +0.8% | +10.3% |
| RPRX | SELL | 2021-07-26 | 2021-07-27 | $39.78 | $712K | -5.6% | -0.7% | -3.9% |
| RPRX | SELL | 2021-07-12 | 2021-07-14 | $42.01 | $1.5M | -2.9% | -5.3% | -11.8% |
| RPRX | SELL | 2021-07-06 | 2021-07-08 | $42.14 | $4.9M | -0.7% | -11.4% | -14.1% |
| RPRX | SELL | 2021-06-04 | 2021-06-08 | $45.76 | $11.4M | -5.4% | -11.1% | -16.2% |
| RPRX | SELL | 2021-06-02 | 2021-06-04 | $42.13 | $2.1M | -4.3% | -8.7% | -13.7% |
| RPRX | SELL | 2021-04-14 | 2021-04-16 | $42.10 | $4.7M | +7.4% | -1.1% | -4.5% |
| RPRX | SELL · 10b5-1 | 2021-04-12 | 2021-04-14 | $42.32 | $15K | +5.7% | -4.2% | -1.7% |
| RPRX | SELL | 2021-03-22 | 2021-03-24 | $46.32 | $4.1M | -1.4% | +1.1% | +1.0% |
| RPRX | SELL | 2021-03-02 | 2021-03-04 | $46.92 | $9.4M | +9.3% | -0.5% | +0.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.